Roth MKM lowered the firm’s price target on TFF Pharmaceuticals to $9 from $12 but keeps a Buy rating on the shares after its Q3 results. The analyst states that despite having 95% of the TFF VORI trial sites open, there was no enrollment update outside of saying that TFFP is well on its way toward having initial data from a subset of the 10 patients by the end of 2023, followed by final data in all 10 patients by the end of Q1 of next year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TFFP:
- TFF Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- TFFP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- TFF Pharmaceuticals publishes research on intranasal delivery of mAbs
- TFF Pharmaceuticals to Hold Third Quarter 2023 Financial and Business Results Conference Call on November 14, 2023
- TFF Pharmaceuticals Congratulates our Scientific Advisory Board Member, Drew Weissman, M.D., Ph.D., for Receiving the Nobel Prize in Physiology or Medicine for his Pioneering Work Enabling the Development of mRNA COVID-19 Vaccines
